Related Experiment Video

Updated: May 23, 2026

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

Targets and delivery methods for therapeutic angiogenesis in peripheral artery disease

Geoffrey O Ouma1, Rebecca A Jonas, M Haris U Usman

  • 1Department of Medicine, Cardiovascular Division, Vascular Medicine Section, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. geoffrey.ouma@uphs.upenn.edu

Vascular Medicine (London, England)
|April 13, 2012
PubMed

Insights

Therapeutic angiogenesis for arterial obstructive diseases shows promise but faces challenges. Research is exploring genetic, cellular, and growth factor delivery for peripheral artery disease (PAD) treatment.

Area of Science:

  • Cardiovascular Research
  • Regenerative Medicine
  • Vascular Biology

Background:

  • Therapeutic angiogenesis aims to treat arterial obstructive diseases by promoting new blood vessel formation.
  • Mechanisms of vasculogenesis, angiogenesis, and arteriogenesis are complex and still under investigation.
  • Current human trials for peripheral artery disease (PAD) using genetic and cellular methods have shown limited efficacy.

Purpose of the Study:

  • To review scientific and clinical advances in therapeutic angiogenesis for peripheral artery disease.
  • To discuss the potential application of these advances in treating ischemic peripheral artery diseases.
  • To explore novel and unconventional therapeutic targets and delivery methods.

Main Methods:

  • Review of scientific literature and clinical trial data on therapeutic angiogenesis.
  • Analysis of genetic, cellular, and bioactive growth factor delivery systems.
  • Evaluation of past and recent developments, including unconventional approaches.

Main Results:

  • Despite ongoing research, translating therapeutic angiogenesis into effective PAD treatments remains a challenge.
  • Advances in delivery systems for genetic, cellular, and growth factors are crucial.
  • Unconventional approaches may offer new therapeutic avenues.

Conclusions:

  • Therapeutic angiogenesis research for PAD is evolving, but clinical translation is lagging.
  • Further investigation into complex vascularization mechanisms is needed.
  • Novel delivery strategies and targets are essential for future PAD therapies.

More Related Videos

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...